Patients with low tumor tissue IL12B mRNA expression had significantly shorter OS than those with high tissue IL12B mRNA expression (HR = 0.64, 95% CI = 0.48–0.86; p = 0.003 for high vs. low expression), which demonstrates a shorter median survival time (1171 d for low expression and 1778 d for high expression). This evidence concerns the gene IL12B and neoplasm.